Condition: Non-infectious Anterior Uveitis · Sponsor: Novaliq GmbH
The primary objective of the study is to investigate the safety and tolerability of NOV05 eye drops at two concentrations QID in patients with active non-infectious anterior uveitis.
This description comes directly from the study's public registry record.
Alice Meides, PhD · +49 622150259 · ameides@novaliq.com
Always discuss trial participation with your own doctor first.
| Horizon Eye & Lasik Center | Phoenix, Arizona, United States | Recruiting |
| Bascom Palmer Eye Institute | Miami, Florida, United States | Recruiting |
| Massachusetts Eye Research and Surgery Institution | Waltham, Massachusetts, United States | Recruiting |
| Metropolitan Eye Research and Surgery Institute | Palisades Park, New Jersey, United States | Recruiting |
| Valley Retina Institute, P.A. | McAllen, Texas, United States | Recruiting |
| Virginia Eye Consultants | Norfolk, Virginia, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07285070